Evidence map›Paper›PMID 26973850›Full record

ArticleOpen forum infectious diseases2016

Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative.

Kimberly Page, Ali Mirzazadeh, Thomas M Rice, Jason Grebely, Arthur Y Kim, Andrea L Cox, Meghan D Morris, Margaret Hellard, Julie Bruneau, Naglaa H Shoukry and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 4 countries.

Kimberly PageDivision of Epidemiology, Biostatistics and Preventive Medicine , University of New Mexico Health Sciences Center , Albuquerque, New Mexico.
Ali MirzazadehDepartment of Epidemiology and Biostatistics , University of California San Francisco.
Thomas M RiceDepartment of Epidemiology and Biostatistics , University of California San Francisco.
Jason GrebelyThe Kirby Institute for Infection and Immunity in Society.
Arthur Y KimHarvard Medical School , Boston, Massachusetts.
Andrea L CoxDepartment of Medicine , Johns Hopkins Medical Institutions , Baltimore, Maryland.
Meghan D MorrisDepartment of Epidemiology and Biostatistics , University of California San Francisco.
Margaret HellardBurnet Institute , Melbourne, Victoria , Australia.
Julie BruneauCentre Hospitalier de l'Université de Montréal , Quebec , Canada.
Naglaa H ShoukryCentre Hospitalier de l'Université de Montréal , Quebec , Canada.
Gregory J DoreThe Kirby Institute for Infection and Immunity in Society.
Lisa MaherThe Kirby Institute for Infection and Immunity in Society.
Andrew R LloydSchool of Medical Sciences , University of New South Wales , Sydney , Australia.
Georg LauerHarvard Medical School , Boston, Massachusetts.
Maria PrinsGGD Public Health Service of Amsterdam , The Netherlands.
Barbara H McGovernSeres Therapeutics , Cambridge, Massachusetts.
Institute of Infection and Immunity · CAUniversity of California, San Francisco · USCentre Hospitalier de l’Université de Montréal · CAHarvard University · USBurnet Institute · AUGGD Amsterdam · NLJohns Hopkins University · USSeres Therapeutics (United States) · USUniversity of New Mexico · USUNSW Sydney · AU

Funding

Virology CoreU19AI082630 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI RAYMOND T CHUNG, GEORG Michael LAUER · 2009 to 2026
$48.1M
Acute Hepatitis C Infection in Young InjectorsR01DA016017 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2002 to 2018
$14.0M
The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, ARTHUR Y · 2005 to 2014
$8.5M
Scientific CoreU19AI088791 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SHAW, GEORGE M · 2010 to 2020
$8.2M
Discovery and Assessment of Genetic Determinants of HCV and HIV ControlR01DA033541 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, KIM, ARTHUR Y · 2011 to 2015
$3.4M
International Collaborative of prospective studies of HIV and Hepatitis in IDUR01DA031056 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2011 to 2015
$2.2M
Understanding the interpersonal context of HIV/HCV risk within injecting dyadsK01DA037802 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORRIS, MEGHAN D · 2014 to 2018
$913k
NIAID NIH HHS U19 AI066345NIAID NIH HHS U19 AI082630NIAID NIH HHS U19 AI088791NIDA NIH HHS K01 DA037802NIDA NIH HHS R01 DA016017NIDA NIH HHS R01 DA031056NIDA NIH HHS R01 DA033541
6 · The paper itself

Abstract

Symptomatic acute HCV infection and interferon lambda 4 (IFNL4) genotypes are important predictors of spontaneous viral clearance. Using data from a multicohort database (Injecting Cohorts [InC3] Collaborative), we establish an independent association between host IFNL4 genotype and symptoms of acute hepatitis C virus infection. This association potentially explains the higher spontaneous clearance observed in some patients with symptomatic disease.

Indexed as

acute infectionalanine aminotransferasehepatitis C virusIFNL4jaundice

Identifiers

PMID26973850
PMCPMC4785397
OpenAlexW2293641492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.